Neos Therapeutics (NASDAQ:NEOS) issued its quarterly earnings data on Thursday, March 15th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.12, Bloomberg Earnings reports. Neos Therapeutics had a negative net margin of 264.80% and a negative return on equity of 437.92%. The firm had revenue of $7.79 million for the quarter, compared to analyst estimates of $9.30 million.
Shares of NEOS stock traded down $0.15 on Friday, reaching $8.15. The company had a trading volume of 173,831 shares, compared to its average volume of 322,208. The company has a debt-to-equity ratio of 7.47, a current ratio of 2.20 and a quick ratio of 1.84. The stock has a market cap of $240.68, a PE ratio of -3.04 and a beta of -0.20. Neos Therapeutics has a 12 month low of $6.30 and a 12 month high of $13.15.
An institutional investor recently raised its position in Neos Therapeutics stock. State Street Corp lifted its holdings in Neos Therapeutics Inc (NASDAQ:NEOS) by 29.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 316,855 shares of the company’s stock after purchasing an additional 72,395 shares during the quarter. State Street Corp owned about 1.16% of Neos Therapeutics worth $2,312,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 49.33% of the company’s stock.
A number of equities research analysts have weighed in on the stock. Cantor Fitzgerald set a $20.00 price target on shares of Neos Therapeutics and gave the stock a “buy” rating in a research note on Friday, March 23rd. Wells Fargo set a $14.00 price target on shares of Neos Therapeutics and gave the stock a “buy” rating in a research note on Saturday, March 17th. Zacks Investment Research upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 22nd. BidaskClub upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 24th. Finally, BMO Capital Markets cut Neos Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. Neos Therapeutics currently has an average rating of “Hold” and a consensus target price of $14.00.
WARNING: “Neos Therapeutics (NEOS) Announces Earnings Results” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/neos-therapeutics-neos-releases-quarterly-earnings-results-beats-estimates-by-0-12-eps.html.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.